Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations research identified that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://samuels813blz4.win-blog.com/profile